How Hong Kong can double asset holdings: target world’s ‘patient’ capital, FSDC advises
Assets under management in Hong Kong would double with the addition of just a small portion of the money global insurance and pension funds have to invest, according to a member of the Financial Development Services Council (FSDC). Hong Kong should do more to attract this so-called patient capital – assets that insurance companies and pension funds invest for the long term, said the government…
Nobel-winning British virologist Sir Michael Houghton has established a programme to create the world's first hepatitis C vaccine while working at Baptist University in Hong Kong. Houghton, who shared the 2020 Nobel Prize in Physiology or Medicine for co-discovering the hepatitis C virus, moved to Hong Kong after the United States and Europe reduced their science spending.
He joined the university after more than four decades in North America, seeking funding and access to Chinese strains of the virus. Houghton plans to begin phase one trials in 2028 in Hong Kong, Shanghai, and Beijing, with the goal of a worldwide vaccine by 2030. The vaccine would initially target high-risk groups such as healthcare workers, newborns, and individuals with multiple sexual partners, costing around HK$1,600 per dose.
Written by urgent.news from South China Morning Post - Hong Kong's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
